Ribo

News

Madrigal builds in MASH with $4.4bn+ Ribo alliance

Already sitting on a blockbuster therapy for MASH, Madrigal has beefed up its pipeline with six siRNA candidates licensed from China's Ribo.

News

RNA specialist Ribo files $205m IPO in Hong Kong

Chinese RNA-based medicine developer Ribo has filed a Hong Kong IPO to raise cash for its siRNA drug for thrombotic diseases.

News

Boehringer targets NASH/MASH with $2bn Ribo alliance

Boehringer Ingelheim has signed a multi-target collaboration with China’s Suzhou Ribo Life Science and its Swedish unit Ribocure to develop treatments for non-alcoholic or

Madrigal builds in MASH with $4.4bn+ Ribo alliance

RNA specialist Ribo files $205m IPO in Hong Kong

Boehringer targets NASH/MASH with $2bn Ribo alliance

Ipsen charts $1.75bn course for Kartos acquisition

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks